Covalent Group bags $8.2m worth of contracts

By Kirsty Barnes

- Last updated on GMT

Related tags: Clinical trial

Covalent Group has managed to bag itself $8.2m (€6.5m) worth of
clinical trial contracts with one pharma giant.

The multiple Phase I and II contracts relate to the development of ain investigatory agent to treat multiple types of influenza, including Avian Flu, said the firm. Specific services will include consulting on clinical trial design and protocol development, project and study site management, field operations, data management, and biostatistical support. The new contracts bring the net value of new contracts signed by Covalent for the year so far to $22.8m - already a 20 per cent increase on the total value of contracts for the whole year of 2005, which reached of $19.1m. The company said it now expects the current quarter to be its second consecutive quarter of profitable operations. Covalent experienced a decline in the level of its clinical trials business at the start of 2006 and this, in addition to start-up delays from several new contracts awarded late in 2005, was cited as a contributing factor in disappointing financial results reported by the firm in its first quarter this year - with net revenues only $2m compared to $3.2m for the comparable 2005 quarter. At the time the contract research organisation (CRO) said it was pinning its hopes on a better second quarter performance and "a return to profitability", which it is now poised to receive, thanks to its succession of new business wins - in August the firm added its tenth new client for the year - eight of which began with consulting contracts, which were later expanded to include contracts for clinical services. Covalent said the latest contract wins were the result of ongoing business development and clinical operations efforts on the part of itself and Remedium Oy, a privately owned, CRO based in Espoo, Finland that it will acquire in november. "We believe that these contract wins represent a strong proof-of-concept that the combination of Covalent and Remedium, resulting in the newly created company Encorium Group, will be a highly competitive force in the drug development and CRO marketplaces," said Kenneth Borow, CEO and president for Covalent Group. "Our belief is supported by the fact that patient recruitment for the Phase II studies included in the current contracts is expected to occur in North America, Scandinavia, the Baltics, and Western, Central and Eastern Europe, where the newly-formed Encorium will have operational capabilities."

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars